Also known as kisspeptin, metastin (45–54), kisspeptin-10, kp-10 · Wikipedia
Kisspeptin (KP-10, Kisspeptin-10, metastin 45-54) is the minimum bioactive C-terminal decapeptide of the KISS1 gene product. With sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, it is the endogenous ligand of the Gq-coupled GPCR KISS1R (formerly GPR54), the principal upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. KP-10 triggers GnRH release from hypothalamic neurons, driving pulsatile LH and FSH secretion. Phase II clinical studies have evaluated it as an IVF oocyte-maturation trigger and in hypogonadotropic hypogonadism, hypothalamic amenorrhea, and hypoactive sexual desire disorder. It is not FDA-approved; KP-54 is the longer-half-life variant favored for IVF triggering.
—
best
price
—
per
mg
—
vendors
tracked
Phase II
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Kisspeptin-10 is the C-terminal decapeptide of KISS1 (metastin) and the minimum active fragment retaining full KISS1R agonism. KISS1R is densely expressed on hypothalamic GnRH neurons; KP-10 binding triggers Gq-mediated phospholipase-C activation, intracellular calcium rise, and depolarization-driven GnRH release.
Pharmacokinetic properties
Half-life
~4 minutes after IV bolus in humans (very short)
Routes
intravenous · subcutaneous
Bioavailability
IV infusion used in most rigorous human studies because of short half-life. SC dosing requires more frequent administration. Oral bioavailability negligible. Cheaper to manufacture than KP-54 due to shorter sequence.
Amino-acid sequence
Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Use & research dosing
Research framing only. Phase I/II human studies typically use intravenous bolus or infusion because of KP-10's very short plasma half-life (~4 minutes). Imperial College London trials have administered KP-10 at 0.1-3.0 nmol/kg as a single IV bolus for sexual-brain-processing and HPG-axis studies, and continuous IV infusions for amenorrhea reactivation. IVF triggering studies have generally favored KP-54 (kisspeptin-54) for its longer half-life (~28 minutes) rather than KP-10. There is no validated subcutaneous or oral protocol; gray-market SC dosing schedules have no controlled efficacy or safety data.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Kisspeptin sits at the apex of the HPG axis and is one of the few peptides with credible human clinical work in both endocrine (IVF triggering, hypogonadotropic hypogonadism, hyperprolactinemic amenorrhea) and sexual-behavior (HSDD brain-imaging) indications, largely driven by the Imperial College London group (Dhillo, Comninos, Abbara). KP-10 is the shorter research variant; KP-54 is preferred for IVF triggering because of its longer half-life. Gray-market subcutaneous protocols for libido have no controlled efficacy or safety evidence and rely on extrapolation from IV-bolus human work.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
medium
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.